TY  - JOUR
AU  - Kostareli, Efterpi
AU  - Hielscher, Thomas
AU  - Zucknick, Manuela
AU  - Baboci, Lorena
AU  - Wichmann, Gunnar
AU  - Holzinger, Dana
AU  - Mücke, Oliver
AU  - Pawlita, Michael
AU  - Del Mistro, Annarosa
AU  - Boscolo-Rizzo, Paolo
AU  - Da Mosto, Maria Cristina
AU  - Tirelli, Giancarlo
AU  - Plinkert, Peter
AU  - Dietz, Andreas
AU  - Plass, Christoph
AU  - Weichenhan, Dieter
AU  - Hess, Jochen
TI  - Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
JO  - Epigenetics
VL  - 11
IS  - 1
SN  - 1559-2308
CY  - Austin, Tex.
PB  - Landes Bioscience
M1  - DKFZ-2017-04963
SP  - 61 - 73
PY  - 2016
AB  - Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9
KW  - Biomarkers, Tumor (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:26786582
C2  - pmc:PMC4846111
DO  - DOI:10.1080/15592294.2015.1137414
UR  - https://inrepo02.dkfz.de/record/128951
ER  -